The next few weeks before Cardiogenics issues quarterly 10Q should be informative. Clearly the company needs funding to continue to operate as a going concern. I anticipate Cardiogenics will complete and announce a PIPE sufficient in size to fund the company through completion of the larger FDA study.

I am doubtful that Cardiogenics will announce the results of the four hospital head-to-head study but hopeful that they will. In my opinion positive results of this clinical trial will move the share price dramatically upward.

Ante